Antibody Engineering & Therapeutics Asia

Antibody Engineering & Therapeutics Asia is organized by KNect365 Life Sciences and will be held from Feb 26 - 28, 2019 at Hilton Tokyo Bay, Tokyo, Kanto, Japan.

Over 3 Days, world-renowned scientists will share the latest technologies, R and D and clinical data to fast-track your next-generation therapeutics towards commercial success. 

Conference session themes will cover 6 critical areas:
• Novel Engineering and Discovery Strategies
• ADCs/Antibody-Drug Conjugates
• Bispecific Antibodies and Multi-Functional Biologics
• Immuno-Oncology
• Preclinical and Clinical Case Studies
• Delivery Strategies and Crossing/Penetrating Biological Barriers

This new conference will bring together renowned industry and academic scientists from around the world to share discovery and development technologies and strategies in the areas of antibody and protein engineering and therapeutics, antibody-drug conjugates (ADCs), bispecifics and immuno-oncology programs. A key feature of the event will be data presented in numerous case studies about preclinical and clinical programs, in which speakers will share lessons learned and challenges overcome.

With over 11 hours of networking time, you will have ample opportunity to find the right partner to accelerate your next generation antibodies to the clinic and beyond.

Time: 9:00 am - 17:00 pm

Prices:
Industry Conference Only: USD 2159.0,
Academic Conference Only: USD 1079.0

Speakers: Tomoyuki Igawa, Ph.D. CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore, Junichi Koga, Ph.D. Head of R and D Division, Executive Officer, Daiichi Sankyo, Japan, Jochen G. Salfeld Vice President, Global Biologics, AbbVie Bioresearch Center, USA, Kouhei Tsumoto, Ph.D. Professor and Director, The University of Tokyo, Japan, Jochen Salfeld, PhD, Vice President Global Biologics.

Additional details will be posted as soon as they are available.